comparemela.com

Latest Breaking News On - Lemaitre vascular inc - Page 2 : comparemela.com

Insider Selling: LeMaitre Vascular, Inc (NASDAQ:LMAT) Director Sells $428,945 00 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) Director Bridget A. Ross sold 5,500 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $77.99, for a total value of $428,945.00. Following the completion of the sale, the director now owns 2,278 shares in […]

Head-To-Head Comparison: InspireMD (NYSE:NSPR) & LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk. Insider & Institutional Ownership 84.6% of LeMaitre Vascular […]

Advancements in Vascular Grafts Market Toward USD 5 7 Billion By 2032 | Market us

Market OverviewThe Global Vascular Grafts Market, which was valued at USD 3.3 billion in 2023, is projected to experience significant growth over the next decade, reaching an estimated USD 5.7 billion by 2032. This growth, representing a Compound Annual Growth Rate (CAGR) of 6.40% from 2023 to 2032, is driven by sev.

LeMaitre Vascular, Inc (NASDAQ:LMAT) Receives Consensus Rating of Moderate Buy from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year […]

Analysts Set LeMaitre Vascular, Inc (NASDAQ:LMAT) Price Target at $73 83

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.